ARANESP Solution Canada - français - Health Canada

aranesp solution

amgen canada inc - darbépoétine alfa - solution - 100mcg - darbépoétine alfa 100mcg - hematopoietic agents

ARANESP Solution Canada - français - Health Canada

aranesp solution

amgen canada inc - darbépoétine alfa - solution - 40mcg - darbépoétine alfa 40mcg - hematopoietic agents

ARANESP Solution Canada - français - Health Canada

aranesp solution

amgen canada inc - darbépoétine alfa - solution - 500mcg - darbépoétine alfa 500mcg - hematopoietic agents

ARANESP Solution Canada - français - Health Canada

aranesp solution

amgen canada inc - darbépoétine alfa - solution - 500mcg - darbépoétine alfa 500mcg - hematopoietic agents

EPREX STERILE SOLUTION 20000IU/ML Canada - français - Health Canada

eprex sterile solution 20000iu/ml

janssen inc - Époétine alpha - solution - 20000unité - Époétine alpha 20000unité - hematopoietic agents

EPREX STERILE SOLUTION 10000IU/ML Canada - français - Health Canada

eprex sterile solution 10000iu/ml

janssen inc - Époétine alpha - solution - 10000unité - Époétine alpha 10000unité - hematopoietic agents

EPREX STERILE SOLUTION 4000IU/ML Canada - français - Health Canada

eprex sterile solution 4000iu/ml

janssen inc - Époétine alpha - solution - 4000unité - Époétine alpha 4000unité - hematopoietic agents

EPREX STERILE SOLUTION 2000IU/ML Canada - français - Health Canada

eprex sterile solution 2000iu/ml

janssen inc - Époétine alpha - solution - 2000unité - Époétine alpha 2000unité - hematopoietic agents

Virbagen Omega Union européenne - français - EMA (European Medicines Agency)

virbagen omega

virbac s.a. - l'interféron oméga recombinant d'origine féline - les immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. chez les chats infectés par le fiv, la mortalité était faible (5%) et n'a pas été influencée par le traitement..

ADVANTAGE MULTI 9 Solution Canada - français - Health Canada

advantage multi 9 solution

elanco canada limited - imidaclopride; moxidectine - solution - 40mg; 4mg - imidaclopride 40mg; moxidectine 4mg - chats; mammifères (divers)